Zobrazeno 1 - 10
of 43
pro vyhledávání: '"E. V. REUTOVA"'
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 172-177 (2022)
Non-small cell lung cancer is a very heterogeneous group of diseases. When choosing an effective patient management strategy, an oncologist focuses on the stage of the disease, the morphological form of the tumor, as well as its molecular genetic mar
Externí odkaz:
https://doaj.org/article/3afa4470b51643a49ee504769c39177e
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 14-20 (2022)
Lung cancer is one of the most common malignant tumors with the highest mortality, with about 85% of cases of the disease being non-small cell lung cancer. To date, adjuvant chemotherapy based on platinum preparations remains the standard of treatmen
Externí odkaz:
https://doaj.org/article/d9480ee32534481e8bfbc13818ee51ec
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 62-67 (2021)
Introduction. Lorlatinib is a third generation ALK tyrosine kinase inhibitor. Back in 2018, the drug underwent accelerated FDA approval and was recommended for the treatment of patients with ALK-positive non-small cell lung cancer after progression o
Externí odkaz:
https://doaj.org/article/1c654f8c443e4a73bbe68d91b0c46fe5
Autor:
D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, V. V. Breder, M. S. Ardzinba, E. V. Reutova, O. I. Borisova
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 18-24 (2021)
Introduction. Lung cancer remains the one of the most common and fatal cancers in the world. For a long time, chemotherapy was the only treatment option for metastatic lung cancer. Currently, immunotherapy became the one of the preferred options of t
Externí odkaz:
https://doaj.org/article/2147954dcc9547a6a6fbf739228a60c2
Autor:
N. V. Marinichenko, K. K. Laktionov, A. V. Nazarenko, E. V. Reutova, Merab S. Ardzinba, V. L. Utkina, T. N. Borisova, A. A. Fedorova, Milada S. Ardzinba
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 209-214 (2020)
For more than 10 years, there have been no significant improvements in treatment outcomes for patients with inoperable locally advanced non-small cell lung cancer. At the moment, the standard of treatment for this category of patients is concurrent c
Externí odkaz:
https://doaj.org/article/c61fc6c4eb424e7690aa5b6de39354ea
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 194-198 (2020)
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EG
Externí odkaz:
https://doaj.org/article/d1c4770fc86945a580bed36e07f1feba
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 176-181 (2020)
Introduction. Sufficient experience has been gained with the use of target drugs in patients with ALK-positive non-small cell lung cancer (NSCLC) over the past years. The multikinase inhibitor crizotinib was the first drug approved for use. The drug
Externí odkaz:
https://doaj.org/article/149e847ae6a048668cf78022bcc88c19
Autor:
A. E. Kuzminov, T. N. Borisova, V. V. Breder, E. V. Reutova, T. D. Barbolina, K. K. Laktionov
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 190-195 (2020)
Introduction. In modern recommendations for the treatment of localized small cell lung cancer (SCLC), preference is given to socalled «early» chemoradiotherapy (CRT), which has a number of limitations due to its pronounced toxicity. With regard to
Externí odkaz:
https://doaj.org/article/70b6de609e474687bfff73e5612c357a
Autor:
D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, O. I. Borisova, V. V. Breder, E. V. Reutova, M. F. Beloyartseva, S. Yu. Kruteleva, I. A. Dzhanyan
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 16-24 (2020)
Recently immune checkpoint inhibitors amazingly changed the landscape of cancer therapy worldwide. The number of immune checkpoint molecules in clinical practice is constantly increasing. There are some monoclonal antibodies recently registered in th
Externí odkaz:
https://doaj.org/article/87179a43c93546bfb40f6596a9ef6212
Publikováno v:
Современная онкология, Vol 22, Iss 3, Pp 85-87 (2020)
The standard approach for stage IB and IIIIIA non-small cell lung cancer (NSCLC), associated with the high risk of relapse, after total lung resection is adjuvant chemotherapy, nowadays. The 5-year survival benefit for this approach is about 5%, and
Externí odkaz:
https://doaj.org/article/0ce8e5769b2f4663b26654a8a7d6d7e7